These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Effects of bempedoic acid on markers of inflammation and Lp(a). Reddy S; Deoker A Curr Opin Cardiol; 2024 Jul; 39(4):280-285. PubMed ID: 38456474 [TBL] [Abstract][Full Text] [Related]
23. Bempedoic acid: a promising novel agent for LDL-C lowering. Agarwala A; Goldberg AC Future Cardiol; 2020 Sep; 16(5):361-371. PubMed ID: 32463301 [TBL] [Abstract][Full Text] [Related]
24. Bempedoic acid for the treatment of hypercholesterolemia. Yang J Expert Rev Cardiovasc Ther; 2020 Jul; 18(7):373-380. PubMed ID: 32532162 [TBL] [Abstract][Full Text] [Related]
25. Real-world utilization of bempedoic acid in an academic preventive cardiology practice. Warden BA; Cardiology BA; Purnell JQ; Duell PB; Fazio S J Clin Lipidol; 2022; 16(1):94-103. PubMed ID: 34924351 [TBL] [Abstract][Full Text] [Related]
26. Bempedoic acid: A new player in lipid-lowering therapies. Cuevas A; Alonso R J Clin Lipidol; 2020; 14(5):615-616. PubMed ID: 32988798 [No Abstract] [Full Text] [Related]
27. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia. Cicero AFG; Fogacci F; Cincione I Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267 [No Abstract] [Full Text] [Related]
28. Review of LDL-C Lowering with Focus on New and Emerging Agents. Brinton EA J Fam Pract; 2020 Sep; 69(7 Suppl):S69-S74. PubMed ID: 33104111 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of bempedoic acid in patients with heterozygous familial hypercholesterolemia: analysis of pooled patient-level data from phase 3 clinical trials. Duell PB; Banach M; Catapano AL; Laufs U; Mancini GBJ; Ray KK; Broestl C; Zhang Y; Lei L; Goldberg AC J Clin Lipidol; 2024; 18(2):e153-e165. PubMed ID: 38341323 [TBL] [Abstract][Full Text] [Related]
30. Clinical evaluation of bempedoic acid for the treatment of hyperlipidaemia. Averna M; Bilato C; Sesti G; Nutr Metab Cardiovasc Dis; 2022 Jan; 32(1):17-20. PubMed ID: 34802854 [TBL] [Abstract][Full Text] [Related]
31. Comprehensive review of statin-intolerance and the practical application of Bempedoic Acid. Yarrarapu SNS; Goyal A; Venkata VS; Panchal V; Sivasubramanian BP; Du DT; Jakulla RS; Pamulapati H; Afaq MA; Owens S; Dalia T J Cardiol; 2024 Jul; 84(1):22-29. PubMed ID: 38521120 [TBL] [Abstract][Full Text] [Related]
32. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials. Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432 [TBL] [Abstract][Full Text] [Related]
33. How Will Our Practice Change After the CLEAR Outcomes Trial? Abrahams T; Nelson AJ; Nicholls SJ Curr Atheroscler Rep; 2024 Mar; 26(3):83-89. PubMed ID: 38294660 [TBL] [Abstract][Full Text] [Related]
34. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase. Bilen O; Ballantyne CM Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902 [TBL] [Abstract][Full Text] [Related]